Monthly Archives: April 2017

 Biopharmaceutical News Week # 15.2017

      Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation, jcm@btobioinnovation.com         Mergers, Acquisitions and Joint Venture   Abbott Laboratories has reached new terms for the acquisition of Alere (Waltham, MA, USA), a competing diagnostic company, for $5.3 billion and both companies have dismissed their respective lawsuits. The agreement comes more than a year […]

read more

Biopharmaceutical News Week # 14.2017

      Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation, jcm@btobioinnovation.com                   Highlights from the AACR (Washington DC, April 1-5)   New Immunotherapy Combination Shows Promise for Patients With Advanced Melanoma Treatment with a combination of ipilimumab (Yervoy) and Coxsackievirus A21 (CVA21; Cavatak), a bioselected, nongenetically altered common cold […]

read more

Biopharmaceutical News Week # 13.2017

      Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation, jcm@btobioinnovation.com     Editor’s Note   There has been an unusual high number of approvals and recommendations of drugs, vaccines, devices and diagnostics during this week, indicating that the innovation process is not slowing down in the first part of 2017.     Business   Merck KGaA […]

read more

Biopharmaceutical News Week # 12.2017

      Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation, jcm@btobioinnovation.com       Editor’s Note       Paris, Berlin, Brussels, Nice and now London have recently been facing horrible terrorist attacks aimed at killing people and destroying our democracies. The incredible resilience of all the harmed or injured individuals, of their families and of many […]

read more

Biopharmaceutical News Week # 11.2017

      Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation, jcm@btobioinnovation.com         US President Donald Trump has chosen Scott Gottlieb to lead the US FDA. Gottlieb, a medical doctor, is currently a fellow at the American Entreprise Institute and has previously served as deputy commissioner for medical and scientific affairs at the FDA during […]

read more

Biopharmaceutical News Week # 10.2017

      Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation, jcm@btobioinnovation.com     Mergers, Acquisitions and Joint Ventures   Otsuka  Pharmaceutical (Tokyo, Japan) acquires Neurovance (Cambridge, MA, USA) for up to $250 million and gets access to centanafadine or EB-1020, a nonstimulant, triple reuptake inhibitor that targets norepinephrine, dopamine, and, to a lesser extent, serotonin reuptake, a […]

read more